Jul 7, 2026 07:00AM
Jul 7, 2026 07:00AM
May 15, 2026 07:30AM
Apr 10, 2026 08:39AM
Apr 10, 2026 08:31AM
Apr 10, 2026 08:30AM
Apr 10, 2026 08:30AM Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
Apr 8, 2026 09:15AM
Mar 19, 2026 07:31AM
Mar 19, 2026 07:30AM
Mar 19, 2026 07:30AM
Mar 19, 2026 07:30AM
Mar 19, 2026 07:30AM
Mar 16, 2026 07:30AM Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
Feb 12, 2026 08:00AM
Feb 12, 2026 08:00AM
Dec 18, 2025 04:35PM
Dec 18, 2025 04:35PM
Dec 18, 2025 04:35PM
Nov 18, 2025 08:45AM
Nov 18, 2025 08:00AM Annovis Bio schedules FDA meeting on Parkinson's dementia drug
Nov 18, 2025 08:00AM
Nov 18, 2025 08:00AM
Nov 18, 2025 08:00AM
Sep 30, 2025 07:05AM
Aug 7, 2025 08:00AM
Aug 7, 2025 08:00AM
Jun 5, 2025 08:00AM Annovis to Host Webinar and Live Q&A on June 24, 2025
Jun 5, 2025 08:00AM
Mar 21, 2025 05:05PM
Feb 5, 2025 08:01AM
Feb 5, 2025 08:00AM
Jan 7, 2025 08:01AM
Jan 7, 2025 08:00AM
Jan 7, 2025 08:00AM FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway
Jan 7, 2025 08:00AM
Nov 25, 2024 08:00AM
Nov 11, 2024 08:00AM
Oct 31, 2024 08:00AM
Oct 16, 2024 06:56AM
Oct 15, 2024 08:03AM
Oct 15, 2024 08:00AM FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs
Oct 2, 2024 08:30AM
Sep 30, 2024 08:05AM
Sep 30, 2024 08:00AM
Sep 3, 2024 07:22AM
Aug 15, 2024 07:00AM
Aug 6, 2024 09:00AM
Aug 6, 2024 08:30AM Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033   
Jul 16, 2024 08:01AM

325,893 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All